Literature DB >> 7249372

Problems associated with the radioimmunoassay of serum trypsin.

C M O'Connor, M D O'Donnell, K F McGeeney.   

Abstract

A commercial trypsin radioimmunoassay (RIA) kit was used for its ability to measure trypsin bound to the serum protease inhibitors, alpha 2 macroglobulin (alpha 2 M) and alpha 1 anti-trypsin (alpha 1 AT). Only 20% of trypsin bound to alpha 2 M and 70% bound to alpha 1 AT was detected by the assay system. Recovery of trypsin added to human serum varied from 0 to 20%. Standard curves prepared from purified human cationic trypsin did not exhibit parallelism with the kit standard curves. Inclusion of horse serum in the standard solutions improved the parallelism observed. Immunoreactive trypsin (IRT) levels obtained for serum samples were found to vary considerably depending on the standard curve used to calculate the assay results. Lower IRT levels were observed when trypsin standards prepared in the absence of horse serum were used as reference.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7249372     DOI: 10.1016/0009-8981(81)90224-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Trypsinogen activation peptides (TAP) concentrations in the peritoneal fluid of patients with acute pancreatitis and their relation to the presence of histologically confirmed pancreatic necrosis.

Authors:  D I Heath; C Wilson; A M Gudgeon; A Jehanli; A Shenkin; C W Imrie
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

2.  Relationship between circulating levels of pancreatic proteolytic enzymes and pancreatic hormones.

Authors:  Sakina H Bharmal; Sayali A Pendharkar; Ruma G Singh; Mark O Goodarzi; Stephen J Pandol; Maxim S Petrov
Journal:  Pancreatology       Date:  2017-09-20       Impact factor: 3.996

3.  Immunoreactive trypsin levels in young cystic fibrosis patients and in other sick children.

Authors:  F M Hallinan; E Tempany
Journal:  Ir J Med Sci       Date:  1983-11       Impact factor: 1.568

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.